Krystal Biotech Inc Stock News

NEW YORK , Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, AAL, KRYS, NVDA, and BABA. Full story available on Benzinga.com

Shares of Krystal Biotech Inc (NASDAQ: KRYS) more than doubled on Monday after the gene therapy company said its pivotal GEM-3 trial for VYJUVEK reported positive topline results. GEM-3 trial met its

•  Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and its secondary endpoint of complete wound healing at three-month timepoints

Krystal Biotech (KRYS) stock is rising higher on Monday thanks to positive results from a recent Phase 3 clinical trial of VYJUVEK. The post KRYS Stock Alert: The Study Results That Have Krystal Biote

Krystal Biotech Inc (NASDAQ: KRYS) has announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa

Metropolitan Life Insurance Co NY lifted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 117,275.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 4,695 shares of the company’s stock after acquiring an additional 4,691 shares during the period. Metropolitan Life Insurance Co NY’s holdings in Krystal Biotech were worth $319,000 as of its most […]

Squarepoint Ops LLC bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 4,501 shares of the companys stock, valued at approximately $306,000. A number of other institutional investors have also recently modified their []

California State Teachers Retirement System lifted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 8.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 24,742 shares of the companys stock after buying an additional 2,010 shares during the quarter. California State Teachers []

PITTSBURGH, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc. , (Krystal) (NASDAQ: KRYS) today announced the presentation of preclinical data supporting the ongoing development of KB303, an innovative, investigational gene-delivery therapy designed to enable local, full-length elastin production in the skin. The data will be presented at the American Society for Dermatologic Surgery (ASDS) 2021 Virtual Meeting to be held November 19-21, 2021.

MetLife Investment Management LLC raised its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 18.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,648 shares of the company’s stock after acquiring an additional 1,015 shares during the quarter. MetLife Investment Management LLC’s […]

Zacks Investment Research upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a sell rating to a hold rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based []

PITTSBURGH, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-cl

PITTSBURGH, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-c